SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "hsv:(MEDICIN OCH HÄLSOVETENSKAP) hsv:(Klinisk medicin) hsv:(Cancer och onkologi) srt2:(2000-2004);srt2:(2001)"

Sökning: hsv:(MEDICIN OCH HÄLSOVETENSKAP) hsv:(Klinisk medicin) hsv:(Cancer och onkologi) > (2000-2004) > (2001)

  • Resultat 11-20 av 161
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
11.
  • Relander, Thomas, et al. (författare)
  • Retroviral transduction of human CD34+ cells on fibronectin fragment CH-296 is inhibited by high concentrations of vector containing medium
  • 2001
  • Ingår i: Journal of Gene Medicine. - 1521-2254. ; 3:3, s. 207-218
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND: The objective of the present study was to optimize conditions for retroviral transduction of human cord blood (CB) CD34+ cells and to reveal mechanisms which interfere with efficient gene transfer. METHODS: An MSCV based retroviral vector with the gene for enhanced green fluorescent protein (MGIN) produced by GP+envAM12 (amphotropic envelope), PG13 (gibbon ape leukemia virus envelope) or 293GPG (vesicular stomatitis virus envelope) cell lines was used to transduce cord blood CD34+ cells on Retronectin (fibronectin fragment CH-296) in three different ways: either in vector containing medium (VCM), in fresh medium on Retronectin pre-loaded with vector or in VCM on Retronectin pre-loaded with vector. RESULTS: Paradoxically, the transduction efficiency obtained with pre-load of vector onto Retronectin alone was higher than pre-load plus VCM for PG13-MGIN (67.9 +/- 6.0% vs 24.9 +/- 8.0%) and AM12-MGIN (47.5 +/- 5.8% vs 38.7 +/- 2.2%). Further experiments showed that transduction on Retronectin pre-loaded with PG13-MGIN or AM12-MGIN was inhibited by the presence of the same VCM at high concentrations, but not by the presence of a VCM with a different receptor specificity. If no pre-load of vector was performed, the highest transduction efficiencies were seen when VCMs were diluted 1:10 (MOIs of 3). The inhibitory effect of high titer PG13-MGIN VCM was confirmed in more primitive CD34+CD38low cells and in NOD/SCID repopulating cells, and was also seen in experiments with bone marrow CD34+ cells. CONCLUSIONS: Retroviral transduction of CB CD34+ cells on Retronectin is inhibited by high titer PG13 and GP+envAM12 vector containing medium. Efficient gene transfer to human hematopoietic cells can be obtained by preload alone of the vector onto Retronectin. These findings are of importance for the design of transduction protocols for repopulating hematopoietic cells.
  •  
12.
  • Asp, Julia, 1973, et al. (författare)
  • Alterations in the regulatory pathway involving p16, pRb and cdk4 in human chondrosarcoma.
  • 2001
  • Ingår i: Journal of orthopaedic research : official publication of the Orthopaedic Research Society. - 0736-0266. ; 19:1, s. 149-54
  • Tidskriftsartikel (refereegranskat)abstract
    • The G1 regulatory pathway involving p16, pRb and cdk4 in the cell cycle has been investigated in human chondrosarcoma. The protein expression of p16, pRb and cdk4 was analyzed by Western blot in cultured cells from eight chondrosarcomas and in two chondrosarcoma cell lines. Both cell lines and one other sample were negative for p16. Moreover, one of the cell lines was pRb-negative and showed a high expression of cdk4 as well. In the other cell line and in three other samples pRb of expected size were detected in addition to a shorter form of the protein. To further investigate the reasons for down-regulation of the p16 protein, the p16-coding gene CDKN2 was analyzed by polymerase chain reaction (PCR), methyl-specific PCR (MSP) and sequencing in all tumor samples as well as in corresponding tumor tissues from three of the samples. The p16-negative samples were all found to have homozygous deletion of CDKN2. Another sample showed partial gene methylation and a heterozygous position in codon 148 was detected in one sample. The same base substitution was also found in two of the tissue samples. Finally, cytogenetic analysis of the samples with homozygously deleted CDKN2 revealed multiple structural abnormalities in all three cases. In conclusion, the p16/pRb/cdk4 pathway may play an important role in the pathogenesis of some chondrosarcomas.
  •  
13.
  • Asp, Julia, 1973, et al. (författare)
  • Changes in p14(ARF) do not play a primary role in human chondrosarcoma tissues.
  • 2001
  • Ingår i: International journal of cancer. Journal international du cancer. - 0020-7136. ; 93:5, s. 703-5
  • Tidskriftsartikel (refereegranskat)abstract
    • The locus encoding the tumor suppressor p16 has been found to code for a second, different protein. This protein, p14(ARF), has been shown to protect p53 from degradation. Like p16, its gene is often altered in different cancers. In this study, the first unique exon, exon 1 beta, of p14(ARF), has been studied in 22 chondrosarcoma tissues using polymerase chain reaction, DNA sequencing and methylation-specific polymerase chain reaction. One chondrosarcoma was found to have exon 1 beta homozygously deleted, but neither mutations nor methylations were found in any of the chondrosarcomas. This indicates that genetic changes of p14(ARF) are a rare event in chondrosarcoma.
  •  
14.
  • Uggla, Bertil, 1962-, et al. (författare)
  • Expression of topoisomerase IIalpha in the G0/G1 cell cycle phase of fresh leukemic cells
  • 2001
  • Ingår i: Leukemia Research. - Oxford, United Kingdom : Elsevier. - 0145-2126 .- 1873-5835. ; 25:11, s. 961-966
  • Tidskriftsartikel (refereegranskat)abstract
    • Topoisomerase IIalpha (topoII alpha) is the target enzyme for several antineoplastic drugs. Correlation between low expression of topo IIalpha and drug resistance has been shown in vitro, but there is limited evidence of a correlation to initial response to treatment or to overall prognosis. Normal cells express topo IIalpha in S/G2/M phase of the cell cycle but not in G0/G1 phase. However, some data suggest that topo IIalpha could be expressed in G0/G1 phase in malignant cells. We have investigated the expression of topo IIalpha in leukemic cells from 25 patients with acute leukemia by flow cytometry, separating cells of different cell cycle phases. We demonstrated that 9/25 samples showed >50% positive cells in G0/G1, and another five samples showed >20%. This finding could possibly provide an explanation to previous difficulties in correlating topo IIalpha expression with clinical outcome. Six of eight patients, where >20% of the cells in G0/G1 were positive for topo IIalpha, entered CR, compared to one of five patients with <20% topo IIalpha positive cells in G0/G1. We suggest that topo IIalpha expression in G0/G1 in leukemic cells may be of predictive value for clinical response to cytostatic drugs.
  •  
15.
  • Andersson, Håkan, 1944, et al. (författare)
  • Comparison of the therapeutic efficacy of 211At- and 131I-labelled monoclonal antibody MOv18 in nude mice with intraperitoneal growth of human ovarian cancer.
  • 2001
  • Ingår i: Anticancer research. - 0250-7005. ; 21:1A, s. 409-12
  • Tidskriftsartikel (refereegranskat)abstract
    • The purpose of the present study was to compare the therapeutic efficacy of the alpha-emitter Astatine-211 with the beta-emitter Iodine-131 bound to the specific monoclonal antibody MOv18. The measurements were performed in an ovarian cancer cell line (NIH:OVCAR 3) growing intraperitoneally in nude mice. Two weeks after the intraperitoneal inoculation of 1 x 10(7) cells of the human ovarian cancer cell line NIH:OVCAR-3 twenty mice were treated intraperitoneally with the specific monoclonal antibody MOv-18 labelled with either 211At (310-400 kBq) or 131I (5100-6200 kBq). The pharmacokinetics and biodistribution of labelled antibody in tumour-free animals were studied and the resulting bone marrow dose was estimated. When the mice were treated with 211At-labelled antibody 9 out of 10 mice were free of macro- and microscopic tumour compared to 3 out of 10 when Iodine-131 was used. The equivalent dose to the bone marrow was 2.4-3.1 Sv from 211At- and 3.4-4.1 Sv from 131I-irradiation. The therapeutic efficacy of 211At-labelled specific antibody is very good and, at approximately equivalent bone marrow doses, better than that of 131I.
  •  
16.
  • Edgren, M, et al. (författare)
  • Angiogenic factors: vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (b-FGF) are not necessarily elevated in patients with advanced renal cell carcinoma.
  • 2001
  • Ingår i: Anticancer research. - 0250-7005. ; 21, s. 1423-
  • Tidskriftsartikel (refereegranskat)abstract
    • Serum analysis of Vascular Endothelial Growth Factor (VEGF) and basic Fibroblast Growth Factor (b-FGF) levels were studied in 53 patients with renal cell carcinoma (RCC). Approximately 2/3 of the patients had disseminated disease at diagnosis, the remainder had no evidence of metastases. The results confirmed that VEGF has a major role in the angiogenesis of RCC. No correlation was observed between VEGF and/or b-FGF and the presence or absence of metastases, nor was any correlation observed between VEGF and/or b-FGF and patient survival. Thus, to utilise VEGF and/or b-FGF as a tumour marker at the time of diagnosis to predict patients with a high risk of progression, where an adjuvant therapeutic approach would be of great value, seems to be limited. Not all patients with RCC exhibited elevated serum levels of VEGF and/or b-FGF. No correlation was observed between tumour stage and serum levels of these angiogenic peptides.
  •  
17.
  • Edgren, M, et al. (författare)
  • Postoperative radiotherapy after prostatectomy can be associated with severe side effects.
  • 2001
  • Ingår i: Anticancer research. - 0250-7005. ; 21, s. 2231-
  • Tidskriftsartikel (refereegranskat)abstract
    • This retrospective study was initiated to evaluate the efficacy and side effects of post-prostatectomy external beam radiation therapy (XRT) with a short time interval between surgery and irradiation in patients with prostate adenocarcinoma. Sixteen patients were investigated. The overall results in this study were 3 deaths due to recurring disease and two relapses after an average follow-up of 60 months. Severe side effects were observed. Two patients required surgical intervention due to severe post-radiotherapy side effects. The reason for this could be the high dose delivered to peripheral organs and/or a too short time interval between surgery and postoperative XRT. The results of this study confirmed that postoperative XRT can improve local control frequency in prostate carcinomas. It is recommended that the time interval between surgery and postoperative radiotherapy should to be 3-6 month.
  •  
18.
  • Eker, Charlotta, et al. (författare)
  • Multivariate analysis of laryngeal fluorescence spectra recorded in vivo
  • 2001
  • Ingår i: Lasers in Surgery and Medicine. - : Wiley. - 0196-8092 .- 1096-9101. ; 28:3, s. 259-266
  • Tidskriftsartikel (refereegranskat)abstract
    • Background and Objective: The potential of using various multivariate analysis methods for classification of fluorescence spectra acquired in vivo from laryngeal tissues in Patients was investigated. Study Design/Materials and Methods: Autofluorescence spectra were measured on 29 normal tissue sites and 25 laryngeal lesions using 337-nm excitation. Four different multivariate analysis schemes were applied. Laryngeal fluorescence spectra from patients who had been administered F-aminolevulinic acid (ALA) were obtained using 405-nm excitation and were classified using partial least squares discriminant analysis (PLS-DA). Results: For autofluorescence spectra, logistic regression based on principal component analysis (PCA) or PLS, or PLS-DA all resulted in sensitivities and specificities around 90% for lesion vs. normal. Using ALA and 405-nm excitation gave a sensitivity of 100% and a specificity of 69%. Conclusion: Multivariate analysis of fluorescence spectra could allow classification of laryngeal lesions in vivo with high sensitivity and specificity. PLS performs at least as well as PCA, and PLS-DA performs as well as logistic regression techniques on these data.
  •  
19.
  •  
20.
  • Sandberg, Tove, et al. (författare)
  • Paracrine stimulation of capillary endothelial cell migration by endometrial tissue involves epidermal growth factor and is mediated via up-regulation of the urokinase plasminogen activator receptor
  • 2001
  • Ingår i: Journal of Clinical Endocrinology and Metabolism. - 1945-7197. ; 86:4, s. 1724-1730
  • Tidskriftsartikel (refereegranskat)abstract
    • Endometrial angiogenesis is not well studied, but has potential as a model for studies of physiological angiogenesis. Migration as well as proliferation of vascular endothelial cells are modulated by other endometrial cells. This study analyzes the chemotactic signal released from endometrial tissue in a wound assay using human microvascular endothelial cells. Endometrial tissue explants stimulate migration, and this effect is significantly weaker with explants taken at midcycle than those obtained earlier or later in the cycle. Migration is inhibited more than 50% by either blocking antibodies to the urokinase plasminogen activator receptor (uPAR) or enzymatic removal of uPAR from the cell surface. Also, migration is inhibited more than 50% by antibodies to epidermal growth factor (EGF), but not by antibodies to vascular endothelial growth factor or basic fibroblast growth factor. The combination, of anti-EGF and anti-uPAR antibodies does not further reduce the response, suggesting that these antibodies target a common pathway. Conditioned medium from endometrial explants contains EGF, and EGF stimulates the migration of endothelial cells in a dose-dependent way. This effect is completely blocked by antibodies to uPAR. These data suggest up-regulation of the uPA system by EGF. Conditioned medium from EGF-treated cells contains less uPA than medium from control cells. In contrast, binding of radiolabeled uPA reveals an increased number of uPA-binding sites in EGF-treated cells. Increased expression of uPAR potentially increases the activation and assembly of focal adhesion sites, a prerequisite for cell migration. We conclude that the endometrial migratory signal has two components. The major part of the signal is blocked by antibodies to EGF, and the response is mediated via upregulation of uPAR in the endothelial cells. The other part of the signal is unknown, and the response does not involve uPAR. Decreased endometrial chemotactic signal at midcycle is probably related to decreased release of EGF, which is secondary to increased binding to endometrial cell membranes.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 11-20 av 161
Typ av publikation
tidskriftsartikel (135)
doktorsavhandling (18)
forskningsöversikt (3)
konferensbidrag (2)
rapport (1)
annan publikation (1)
visa fler...
bokkapitel (1)
visa färre...
Typ av innehåll
refereegranskat (141)
övrigt vetenskapligt/konstnärligt (20)
Författare/redaktör
Borg, Åke (14)
Fernö, Mårten (7)
Bendahl, Pär Ola (6)
Wolk, A (6)
Mertens, Fredrik (6)
Olsson, Håkan (5)
visa fler...
Manjer, Jonas (5)
Berglund, Göran (5)
Möller, Torgil (4)
Hultborn, Ragnar, 19 ... (4)
Ahlman, Håkan, 1947 (4)
Wängberg, Bo, 1953 (4)
Baldetorp, Bo (4)
Andersson-Engels, St ... (3)
Nilsson, Ola, 1957 (3)
Larsson, Christer (3)
Mertens, F (3)
Brun, Eva (3)
Svanberg, Katarina (3)
Forssell-Aronsson, E ... (3)
Hallberg, Bengt (3)
Höglund, Mattias (3)
Bergh, J (2)
Olsson, H. (2)
Naredi, Peter, 1955 (2)
Jerkeman, Mats (2)
Elmståhl, Sölve (2)
Mani, Katrin (2)
Ringberg, Anita (2)
Romain, S (2)
Nyman, Jan, 1956 (2)
Björk-Eriksson, Thom ... (2)
Ahlner-Elmqvist, Mar ... (2)
Wennerberg, Johan (2)
Johansson, Bertil (2)
Malina, Janne (2)
Adami, H-O (2)
Miller, A. B. (2)
Damber, Jan-Erik (2)
Bendsöe, Niels (2)
Påhlman, Sven (2)
Lindahl, Anders, 195 ... (2)
Carlén, Birgitta (2)
Lindblom, Annika (2)
Englund, Elisabet (2)
Nilsson, S. (2)
Kölby, Lars, 1963 (2)
Fransson, Lars-Åke (2)
Gustafsson, Lotta (2)
Spiegelman, D (2)
visa färre...
Lärosäte
Lunds universitet (97)
Göteborgs universitet (27)
Karolinska Institutet (26)
Uppsala universitet (22)
Umeå universitet (11)
Linköpings universitet (7)
visa fler...
Örebro universitet (6)
Handelshögskolan i Stockholm (2)
Kungliga Tekniska Högskolan (1)
Stockholms universitet (1)
Högskolan i Gävle (1)
Jönköping University (1)
Chalmers tekniska högskola (1)
visa färre...
Språk
Engelska (160)
Svenska (1)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (161)
Naturvetenskap (2)
Teknik (1)
Samhällsvetenskap (1)
År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy